NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan.
Proof of principle needed before launching “big science” program, advisors say.
Also in this 12-page issue: NCI’s Lance Liotta and FDA’s Emanuel Petricoin to move to George Mason University.
Zvi Fuks of Memorial Sloan-Kettering arrested and charged with securities fraud related to sale of ImClone stock.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%









